Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expands By 33.6%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,830,000 shares, an increase of 33.6% from the March 15th total of 1,370,000 shares. Currently, 5.5% of the shares of the company are short sold. Based on an average daily volume of 313,200 shares, the days-to-cover ratio is currently 5.8 days.

iTeos Therapeutics Stock Up 4.7 %

ITOS stock traded up $0.29 on Friday, reaching $6.51. 1,010,374 shares of the company’s stock were exchanged, compared to its average volume of 471,606. iTeos Therapeutics has a twelve month low of $4.80 and a twelve month high of $18.75. The stock has a fifty day moving average of $6.61 and a 200-day moving average of $7.69. The firm has a market cap of $248.64 million, a PE ratio of -2.07 and a beta of 1.43.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13. On average, equities research analysts predict that iTeos Therapeutics will post -3.49 EPS for the current fiscal year.

Institutional Investors Weigh In On iTeos Therapeutics

Several institutional investors have recently modified their holdings of ITOS. Exchange Traded Concepts LLC boosted its position in iTeos Therapeutics by 25.1% during the first quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company’s stock worth $103,000 after purchasing an additional 3,468 shares in the last quarter. Wellington Management Group LLP grew its holdings in iTeos Therapeutics by 4.3% during the 4th quarter. Wellington Management Group LLP now owns 110,332 shares of the company’s stock valued at $847,000 after buying an additional 4,563 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in iTeos Therapeutics by 192.2% during the fourth quarter. Public Employees Retirement System of Ohio now owns 84,220 shares of the company’s stock worth $647,000 after buying an additional 55,394 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in shares of iTeos Therapeutics by 266.7% in the fourth quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock worth $845,000 after acquiring an additional 80,000 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $42,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ITOS shares. JPMorgan Chase & Co. dropped their price target on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th. Finally, Wells Fargo & Company lowered their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.